Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138959 | 1.00 | RPS6KA3 (0.39) | RPS6KA3CACNA1BSLC22A12MAPK14CYP11B2 | |
| SCHEMBL315521 | 0.90 | CYP1A2 (0.31) | RPS6KA3 | |
| SCHEMBL315520 | 0.90 | CYP1A2 (0.31) | RPS6KA3 | |
| SCHEMBL2142775 | 0.87 | CACNA1B (0.39) | CACNA1BSLC22A12CYP11B2CYP11B1 | |
| SCHEMBL2142779 | 0.87 | CACNA1B (0.39) | CACNA1BSLC22A12CYP11B2CYP11B1 | |
| SCHEMBL2141856 | 0.86 | RPS6KA3 (0.41) | RPS6KA3CACNA1BSLC22A12CYP11B2CYP11B1 | |
| SCHEMBL2141850 | 0.86 | RPS6KA3 (0.41) | RPS6KA3CACNA1BSLC22A12CYP11B2CYP11B1 | |
| SCHEMBL315265 | 0.85 | HPGDS (0.37) | CYP11B2CYP11B1GSK3B | |
| SCHEMBL315266 | 0.85 | HPGDS (0.37) | CYP11B2CYP11B1GSK3B | |
| SCHEMBL2141864 | 0.85 | SLC22A12 (0.40) | SLC22A12CYP11B2CYP11B1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148407-B2 | Compounds derived from 5-thioxylose and their use in therapeutics | LABORATORIES FOURNIER S.A. (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | INVENTIVA (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1861411-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100413-A9 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | FOURNIER LAB SA (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006100413-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | TPMT, STS, TBXAS1 | RPS6KA3 1866/4885CACNA1B 4674/4885SLC22A12 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.